University of Rhode Island

DigitalCommons@URI
Institute for Immunology and Informatics
Faculty Publications

Institute for Immunology and Informatics
(iCubed)

2011

HelicoVax: Epitope-based therapeutic Helicobacter pylori
vaccination in a mouse model
Steven F. Moss
Leonard Moise
University of Rhode Island, lmoise@uri.edu

Dong Soo Lee
Woojin Kim
Songhua Zhang

See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/immunology_facpubs

This is a pre-publication author manuscript of the final, published article.

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative
Works 4.0 License.
Citation/Publisher Attribution
Moss, S. F., Moise, L., Lee, D. S., Kim, W., Zhang, S., Lee, J., Rogers, A. B.,...De Groot, A. S. (2011).
HelicoVax: Epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine, 29(11),
2085-2091. doi: 10.1016/j.vaccine.2010.12.130
Available at: https://doi.org/10.1016/j.vaccine.2010.12.130

This Article is brought to you for free and open access by the Institute for Immunology and Informatics (iCubed) at
DigitalCommons@URI. It has been accepted for inclusion in Institute for Immunology and Informatics Faculty
Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.

Authors
Steven F. Moss, Leonard Moise, Dong Soo Lee, Woojin Kim, Songhua Zhang, Jinhee Lee, Arlin B. Rogers,
William Martin, and Anne S. De Groot

This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/immunology_facpubs/96

NIH Public Access
Author Manuscript
Vaccine. Author manuscript; available in PMC 2012 March 3.

NIH-PA Author Manuscript

Published in final edited form as:
Vaccine. 2011 March 3; 29(11): 2085–2091. doi:10.1016/j.vaccine.2010.12.130.

HelicoVax: Epitope-based therapeutic H. pylori vaccination in a
mouse model
Steven F. Moss1,*, Leonard Moise2,3, Dong Soo Lee1, Woojin Kim1, Songhua Zhang1,
Jinhee Lee4, Arlin B. Rogers5, William Martin2, and Anne S. De Groot2,3,6
1

Department of Medicine, Division of Gastroenterology, Rhode Island Hospital & Warren Alpert
Medical School of Brown University, Providence, Rhode Island 2 EpiVax, Inc., Providence, Rhode
Island 3 Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode
Island 4 University of Massachusetts Medical School, Worcester, Massachusetts 5 Department of
Pathology, University of North Carolina, Chapel Hill, North Carolina 6 Department of Pediatric
Infectious Disease, Brown University Warren Alpert Medical School, Providence, Rhode Island

NIH-PA Author Manuscript

Abstract
Helicobacter pylori is the leading cause of gastritis, peptic ulcer disease and gastric
adenocarcinoma and lymphoma in humans. Due to the decreasing efficacy of anti-H. pylori
antibiotic therapy in clinical practice, there is renewed interest in the development of anti-H. pylori
vaccines. In this study an in silico-based approach was utilized to develop a multi-epitope DNAprime/peptide-boost immunization strategy using informatics tools. The efficacy of this construct
was then assessed as a therapeutic vaccine in a mouse model of gastric cancer induced by chronic
H. pylori infection. The multi-epitope vaccine administered intranasally induced a broad immune
response as determined by interferon-gamma production in ELISpot assays. This was associated
with a significant reduction in H. pylori colonization compared with mice immunized with the
same vaccine intramuscularly, given an empty plasmid, or given a whole H. pylori lysate
intranasally as the immunogen. Total scores of gastric histological changes were not significantly
different among the 4 experimental groups. These results suggest that further development of an
epitope-based mucosal vaccine may be beneficial in eradicating H. pylori and reducing the burden
of the associated gastric diseases in humans.
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Introduction
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Helicobacter pylori represents a significant public health challenge since it causes chronic
gastritis and significantly increases the risk of developing peptic ulcer disease and gastric
cancer [1]. H. pylori infection is highly prevalent, particularly in developing countries. The
strong epidemiological linkage between H. pylori and distal (non-cardia) cancer led the
World Health Organization's International Agency for Cancer Research branch to classify H.
pylori as a definite (type I) carcinogen in 1994 [2], a conclusion confirmed by the same
agency last year [3].
The co-evolution of H. pylori with human beings over tens of thousands of years and the
inverse relationship between H. pylori and certain conditions, such as gastroesophageal
reflux disease, has led to the suggestion that persistent H. pylori infection may provide some
benefit to humanity, especially in the developed world [4]. Nevertheless, for most infected
individuals the balance of evidence supports eradicating H. pylori to prevent gastritis, ulcer
disease and gastric cancer, especially where H. pylori and gastric cancer are very common,
such as in the Asian-Pacific region [5].
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Current treatments to eradicate H. pylori involve the use of multiple antibiotics in
combination with acid suppression medication over 1-2 weeks, an approach that has
changed little over the last 3 decades since H. pylori was first identified [1]. Because of
antibiotic resistance (especially to metronidazole and clarithromycin), H. pylori is more
difficult to eradicate now than it had been formerly [6] leading to renewed interest in
developing alternative therapeutic strategies such as vaccines [7]. Vaccination against H.
pylori may be a particularly attractive choice as the most practical way to avoid H. pyloriassociated gastric cancer in the developing world [8].
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In humans, H. pylori stimulates an intense gastric inflammatory response that persists over
the course of infection that typically lasts many decades. Animal models have established
that the pathogenesis of gastric diseases induced by H. pylori is related to the Th1-skewed
T-cell response and that humoral immunity does not provide protection against infection.
Despite the generation of robust cellular and humoral immune responses, spontaneous
eradication of the organism is extremely rare in humans [1], likely related to several
properties of the bacterium that help it evade natural immune responses and allow
persistence [4]. While normal immune mechanisms fail to eradicate H. pylori, some
prophylactic and therapeutic vaccines strategies using a wide variety of H. pylori antigens
have been reported to successfully eradicate H. pylori from mice and in a few studies in
human volunteers [7]. Nevertheless the correlates of gastric immunity to H. pylori are not
well defined and the optimal choice of antigen and best delivery method for further clinical
development remain to be determined.
In order to advance our H. pylori vaccine strategy we used a gene-to-vaccine approach,
incorporating multiple epitopes in a DNA-prime/peptide boost approach as previously
described [9], using informatics tools that have been successfully applied to AIDS, TB,
smallpox and tularemia vaccine development [9-13]. We present our initial findings on the
efficacy of this construct as a therapeutic vaccine in a mouse model of gastric cancer
induced by chronic H. pylori infection. Our results suggest that a broad-spectrum epitopedriven immune response against H. pylori antigens can lead to successful eradication of the
organism.
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Methods
Mice, H. pylori infection and overall experimental plan
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A total of 80 male and female C57BL/6 mice deficient in the CDKN1B gene encoding p27
were used in this study. Because female heterozygous CDKN1B-deficient mice are sterile,
the mice for this study were derived from breeding male homozygous deficient to female
heterozygotes and then identifying homozygous deficient pups by genotyping. Heterozygote
founders of this colony had been originally purchased from Jackson laboratories (Jackson
Labs, Bar Harbor, ME). All studies were performed in full compliance with the standards of
the Rhode Island Hospital Institutional Animal Care and Use Committee and in accordance
with NIH publications entitled “Principles for Use of Animals” and “Guide for the Care and
Use of Laboratory Animals.”
At 6 weeks of age mice were infected with 109 H. pylori strain SS1 in 0.1 mL PBS by
gavage on 3 occasions over 1 week using a balled animal feeding needle as previously
described [14].
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There were 4 experimental groups (20 mice per group); the experimental design is shown in
Figure 1. At weeks 11-15 of age, mice were given doses of a H. pylori SS1 lysate, an empty
plasmid (“pVAX control”) or a DNA based vaccine intramuscularly or intranasally. At ages
17 and 18 weeks mice were given a boost of intranasal peptides formulated in liposomes (or
empty liposome as a control).
All mice were maintained in micro-isolator cages to reduce inter-cage Helicobacter
infection and allowed access to Harlan Teklad Global Diet 2018 (Harlan, Indianapolis, IN)
and water ad libitum, in accordance with the guidelines set forth by the Institutional Animal
Care and Use Committee of Rhode Island Hospital. At 51 weeks of age (45 weeks after H.
pylori infection) mice were euthanized by cervical dislocation under isoflurane anesthesia
for bacteriological, immunological and histological analyses.
Immunizations
A lysate of H. pylori strain SS1 was prepared by French press and clarified by centrifugation
as described previously [15]. 200 microgram of H. pylori lysate with 10 microgram E. coli
heat-labile LT (R192G) adjuvant in 20 microliters PBS was administered intranasally once
weekly for 5 weeks. [16].

NIH-PA Author Manuscript

In the group receiving pVAX control intranasally, 100 micrograms of an empty plasmid was
given with 10 microgram LT (R192G) adjuvant in 20 microliters PBS on 3 occasions over 5
weeks (weeks 11,13 and15), and 20 microliters PBS only was given intranasally on two
occasions (weeks 12 and 14).
In the group receiving DNA vaccine intramuscularly, 100 micrograms of DNA in 0.1
milliliter PBS was given into the flank on 3 occasions over 5 weeks (weeks 11,13 and 15)
and 20 microliters PBS only was given intranasally on two occasions (weeks 12 and 14).
In the group receiving DNA vaccine intranasally, 100 micrograms of DNA was given with
10 microgram LT (R192G) adjuvant in 20 microliters PBS on 3 occasions over 5 weeks
(weeks 11,13 and 15) and 20 microliters PBS only was given intranasally on two occasions
(weeks 12 and 14).
To boost responses in the two DNA-based vaccine arms, a 10 microliter volume of
liposomal peptide vaccines (50 microgram) with 20 microgram immunostimulatory CpG
oligonucleotides and 10 microgram LT (R192G) were given intranasally at week 17 and at
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week 19. All peptides were formulated together in a single preparation so that all the mice
treated with peptides receive the identical peptide combination. The other two groups of
mice (H. pylori lysate, pVax control) were given empty liposomes instead, at the same
timepoints.
Multi-epitope DNA vaccine engineering
Epitope sequences were concatenated to form two multi-epitope genes (termed HelicoVax A
and HelicoVax B), each containing 25 HLA Class II epitopes that were identified by
immunoinformatics methods, as described previously [17]. The detailed final composition
and epitope order are listed in Supplemental Table 1 and Supplemental Table 2. All mice in
the DNA vaccine groups received both HelicoVax A and HelicoVax B. Initially, epitopes
were assembled in a random sequence. To avoid creation of novel epitopes at epitope
junctions, an algorithm which iteratively re-orders epitopes to reduce junctional
immunogenicity (VaccineCAD) was used to optimize epitope order [10]. In addition, GlyPro-Gly-Pro-Gly spacer sequences were engineered between some epitopes to optimize
epitope processing, where re-ordering by VaccineCAD did not sufficiently reduce potential
junctional immunogenicity [18].
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A Kozak sequence was engineered upstream of the coding sequence for efficient translation
initiation. To target the immunogens to the Class II processing pathway, the tissue
plasminogen activator (tPA) leader sequence (MQMSPALTCLVLGLALVFGEGSA) was
placed upstream of epitope sequences to direct translation products to the secretory pathway.
A histidine tag was incorporated downstream of the epitope sequences followed by two stop
codons. Genes were synthesized by GeneArt (Burlingame, CA) and subcloned at predetermined flanking restriction sites into pVAX1 (Invitrogen, Carlsbad, CA), a DNA
vaccine vector that accommodates FDA recommendations for construction of plasmid DNA
vaccines [19]. High purity plasmids for immunizations were prepared by PureSyn, Inc.
(Malvern, PA) at pre-clinical grade.
Peptide vaccine preparation
Peptides were manufactured using 9-fluoronylmethoxycarbonyl (Fmoc) chemistry by New
England Peptide (Gardner, MA). Master batch records indicate that peptides were purified to
>80% as ascertained by analytical reversed phase HPLC and peptide mass was confirmed by
MALDI-TOF mass spectrometry.
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The constituent peptides of the DNA vaccine were formulated in liposomes with
immunostimulatory CpG oligodeoxynucleotide (ODN) 1555 (5′GCTAGACGTTAGCGT-3′; Integrated DNA Technologies, Coralville, IA) [20] and heatlabile enterotoxin, LT (R192G), kindly provided by Dr. John Clements (Tulane University).
Sterically stable cationic liposomes were prepared from three lipid components: 11.9 μmol
dioleylphosphatidylethanolamine, 7.9 μmol dimethylaminoethanecarbamol-cholesterol, and
1.1 μmol polyethylene glycol 2000-phosphatidyl-ethanolamine (Avanti Polar Lipids,
Alabaster, AL). The lipids were mixed, dried in a rotary evaporator and re-suspended in PBS
to make empty multi-lamellar vesicles. These vesicles were then sonicated for 2 min to
convert them into unilamellar liposomes. Unilamellar liposomes (10 μmol) were mixed with
CpG ODN (400 μg) and peptides (1 mg), flash frozen and freeze-dried overnight. To
encapsulate CpG ODN and peptides in liposomes, the resulting powder was re-suspended
with sterile distilled water and vortexed for 15 seconds every five minutes for 30 minutes at
room temperature. PBS and LT (R192G) were added to yield the final required vaccine
volume and LT dose, as described above. Liposome formulations were stored at 4°C until
use.
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H. pylori quantification
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H. pylori infection was quantified by real-time PCR of the SSA gene of H. pylori,
normalized for mouse stomach GAPDH expression, as previously described [14].
Gastric histology
Gastric histology was evaluated without knowledge of experimental group in H&E-stained
sections and scored for epithelial and inflammatory cell parameters using the criteria and
grading system of Rogers et al [21].
ELISpot assay
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The frequency of epitope-specific splenocytes was determined by IFN-gamma ELISpot
assay using the Mabtech IFN-gamma ELISpot Kit according to the manufacturer's protocol
(Mariemont, OH). Briefly, spleens were harvested from groups of control and vaccinated
mice and mascerated to produce single cell splenocyte suspensions in RPMI-10% fetal
bovine serum-1% penicillin/streptomycin-1% L-glutamine-0.1% BME at a concentration of
3 × 106 cells/ml. Cells were transferred at 3×105/well to ELISpot plates pre-coated with
anti-murine IFN-gamma by the manufacturer and stimulated with 50 individual and 6 pools
of 5-10 peptides at 10 μg/ml in triplicate wells. Pools 1 to 3 correspond to the epitopes
contained in DNA vaccine construct A (HelicoVaxA) and pools 4 to 6 correspond to
epitopes present in DNA vaccine construct B (HelicoVaxB). Positive controls included cells
stimulated with Con A (2 μg/ml) or SS1 lysate (10 μg/ml); no-peptide stimulation served as
a negative control. ELISpot plates were incubated at 37°C, 5% CO2 for 2 days, washed,
incubated with a secondary HRP labeled anti-IFN-gamma antibody and developed by
addition of TMB substrate. Spot counts were determined by Zellnet, Inc. using a Zeiss
ELISpot plate reader. Results were recorded as the average number of spots over
background and adjusted to spots per one million cells seeded. Responses are considered
positive if the number of spots is: 1) at least twice greater than background, 2) greater than
50 spots forming cells per one million splenocytes over background (i.e. one response over
background per 20,000 splenocytes), and 3) statistically significant by Student's t-test in
comparison with the corresponding spot forming cell data set for other groups (p<0.05).
Statistics
Differences between experimental groups were compared by one-way analysis of variance
with Dunnett's multiple comparison test, or the non-parametric equivalent, Kruskal-Wallis
with Dunn's multiple comparison test, as appropriate (GraphPad Prism version 5.01,
GraphPad, La Jolla, CA).
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Results
Multi-epitope DNA vaccine construction
We designed two DNA vaccines, HelicoVax A and HelicoVax B, each of which contains a
distinct set of 25 HLA class II epitopes (Figure 2 and Table 1). The epitopes were previously
identified using immunoinformatics methods that selected immunogenic and conserved
sequences from the H. pylori 26695 and J99 genomes [17]. Epitope sequences were
randomly concatemerized, at first. To avoid production of neo-epitopes at epitope junctions,
the VaccineCAD algorithm was used to re-arrange epitopes in an order that diminishes
potential junctional immunogenicity. The default order for each construct contained
significant predicted immunogenicity at two junctions in HelicoVax A and none in
HelicoVax B (EpiMatrix scores >10). Re-ordering of epitopes by VaccineCAD and insertion
of GPGPG spacers (24) produced sequences with minimized junctional immunogenicity
(EpiMatrix scores < 4.5) (Supplemental Data Tables 1 and 2).
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H. pylori colonization
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A small number of mice died due to peri-procedural complications, so that the final numbers
of mice available at study end were 18 in the lysate and DNA IM groups, 17 in the empty
plasmid control group and 19 in the DNA IN group.
The results of H pylori infection density evaluated by real-time PCR are shown in Figure 3.
Mice in the DNA IN group had the lowest numbers of bacteria, with 5 of the 19 mice having
no detectable H. pylori DNA (compared with 2 of 17 in the pVAX group, none of 18 in the
lysate group and 3 of 18 in the DNA IM group). Considerable variation in infection density
within each group was evident, but the median value for the DNA IN group (1.05) was
significantly lower than the median for each of the other 3 groups, lysate median 47.4,
pVAX median 25, DNA IM median 53.4 (P<0.001 versus lysate, P<0.01 versus pVAX, and
P<0.001 versus DNA IM).
Histology
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Histological abnormalities in these mice are shown in Table 2, including the median (range)
scores for inflammation, epithelial defects, oxyntic atrophy, hyperplasia, metaplasia and
dysplasia, as well as total score. Overall, the histological changes were quite mild and
differences were only statistically significant for inflammation and dysplasia, when
comparing mice treated with pVAX versus lysate (less advanced histological changes in the
pVAX group, P<0.05 for inflammation, P<0.01 for dysplasia).
Immune responses
ELISpot assays of epitope-stimulated splenocytes in the DNA IN and DNA IM groups
demonstrated that 33/50 epitopes (66%) stimulated >50 interferon-gamma spot forming cells
per million splenocytes (Figure 4, gray bars), compared to only 2/50 epitopes (4%) which
were recognized in SS1 lysate-immunized animals (Figure 4, open bars). Additionally, all
peptide pools stimulated robust interferon-gamma production. There was no consistent
difference between intranasal (filled circles) and intramuscular (open circles) DNA
immunization on the single-epitope level, but intranasal vaccination generally was
associated with stronger responses, particularly among the most immunogenic epitopes.
Consistent with the colonization data, SS1 lysate and DNA IM groups, respectively,
stimulated 2 and 6 statistically significant responses when compared to the pVAX group,
while 23 significant responses were observed in the DNA IN group (P<0.05). pVAX alone
did not stimulate any statistically significant ELISpot responses

Discussion
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The results of this study suggest that a DNA-prime/peptide-boost vaccine designed to
present multiple H. pylori epitopes has therapeutic efficacy when delivered intranasally to
mice previously infected by H. pylori. The multi-epitope vaccine induced a broad immune
response that led to a significant reduction in H. pylori colonization. In contrast, mice given
a whole H. pylori lysate or an empty plasmid intranasally as the immunogen, or immunized
with the same vaccine intramuscularly failed to eradicate the organism. These encouraging,
though preliminary, results suggest that further development of an epitope-based mucosal
vaccine against H. pylori can potentially lead to a novel approach to prevent H. pyloriassociated diseases such as peptic ulcer disease and gastric cancer in humans.
Importantly, the vaccine-induced immune response parallels what is observed in natural
infection. H. pylori infection dramatically influences the gastric leukocyte environment with
recruitment of T cell populations, primarily the CD4+ phenotype [22], that constitute an
enriched source (~1-10%) of H. pylori-specific T cells compared with peripheral T
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lymphocytes [23,24]. Gastric T cells isolated from biopsies of H. pylori-infected subjects
exhibit a predominantly proinflammatory Th1 phenotype characterized by a high frequency
of IFN-γ-secreting cells [22,25]. The finding that live H. pylori preferentially stimulates
production of IL-12 [26], which selects for Th1 cell development, may explain the finding
that the majority of Th cell clones derived from H. pylori-infected patients are comprised of
Th1 effector cells [23,27]. H. pylori pathogenesis also involves regulatory T cells (Tregs).
Depletion of CD4+/CD25hi Tregs from infected human donors leads to increased H. pylorispecific memory T cell proliferation and IFN-gamma production in response to H. pylori
pulsed dendritic cells. Additionally, increased levels of CD4+/CD25hi/FoxP3+ regulatory T
cells have been observed in gastric and duodenal mucosa of H. pylori-infected humans [28].
Moreover, similar results have been described in mouse models of H. pylori infection
[29,30]. These findings underscore the importance of a Treg response in H. pylori
immunopathogenesis and suggest that persistence of H. pylori infection may be explained by
Treg-mediated suppression of pathogen-specific memory T-cells [31]. As Tregs contribute
to equilibrium between host and pathogen, inflammation is maintained at low levels,
allowing H. pylori to survive. Taken together, immunopathogenesis studies suggest that a
vaccine that elicits a strong Th1 response, like the CD4+ T-cell epitope-based vaccine
described here, should support the immune system's fight against H. pylori infection.
However, we appreciate that identifying correlates of vaccine efficacy against H. pylori
remains a major challenge [7].
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The CDKN1B deficient mouse model was chosen for this study because it had been shown
to develop gastric cancer about 1 year after H. pylori infection, following a sequence of
progressive histological changes (gastritis, glandular atrophy, metaplasia and dysplasia)
similar to the events that appear during gastric carcinogenesis in humans infected by H.
pylori [14]. One of the aims of this study was to determine whether the therapeutic vaccine
could inhibit these progressive histological changes and thus prevent cancer in this model.
However histological changes in all four arms of this study were relatively mild, even in the
group that received no immunogen (the pVAX group). Indeed, histological abnormalities
evaluated at 45 week post-infection were, if anything, less severe in those mice that received
the pVAX construct than in mice that had been exposed to H. pylori lysate or the epitope
based H. pylori DNA vaccines. Although it might be assumed that reduction in H. pylori
colonization will lead to less inflammation and other features of gastric damage included in
the histological score, it is important to note that within groups of C57BL/6 mice
successfully infected by the SS1 H. pylori strain, there is an inverse relationship between the
bacterial load and the total gastritis score [32]. Another important consideration when
interpreting histological changes is the phenomenon of “post immunization gastritis” in
which successful elimination of H. pylori following vaccination is accompanied by a
transient increase of gastritis over a few weeks, though this ultimately abates with time [33].
The current study evaluated inflammation only at the end of the experiment and therefore
the kinetic changes in gastritis over the course of the 45 week infection period remains
unknown; it is conceivable that post-immunization gastritis (presumably absent in the pVAX
group) might account for some of the discrepancy between the histological scores and the H.
pylori colonization at 45 weeks post infection.
A limitation of the current study is that we did not include a group of mice that were
infected with H.pylori but were not subsequently subject to any subsequent experimental
manipulations at all (a true “negative control” group). Thus, we cannot state with certainty
that the DNA IM strategy or the HP lysate strategy (or indeed the pVAX control) did not
reduce H.pylori colonization. We can only state with certainty that the DNA IN strategy was
superior to the other 3 strategies. Indeed, because all mice in the study received LT as
adjuvant, a non-specific effect of adjuvant also cannot be entirely ruled out. We suspect that
the intranasal route to deliver the epitope-based DNA vaccine was more efficacious than the
Vaccine. Author manuscript; available in PMC 2012 March 3.

Moss et al.

Page 8

NIH-PA Author Manuscript

identical vaccine delivered intramuscularly because mucosal immunization likely produced
a more robust gastric mucosal cell-mediated immune response against H.pylori. However,
further studies will be necessary to directly test this hypothesis.
Despite decades of research, the immune response to H. pylori and, in particular, the
correlates of successful immunity necessary for H. pylori vaccination remain poorly
understood. Based upon many previous studies in animal models of infection it is known
that the production of antibody in the stomach (IgA) provides little or no protection against
H. pylori infection [34]. In contrast MHC Class II restricted T-cells including Th1, Th2 and
Th17 cells are important in mediating immunity in murine models [7]. In humans, chronic
infection by H. pylori is associated with robust immune and inflammatory responses that
nevertheless rarely succeed in eradicating the organism and decades long persistence is
typical, related in part to the strategy of H. pylori to survive and evade immune defenses [4].
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The choice of the CDKN1B mouse as a model for testing the potential therapeutic efficacy
of an epitope based vaccine against H. pylori was predicated upon increased susceptibility of
these mice to gastric cancer and the opportunity to determine whether therapeutic
immunization against H. pylori could reduce recurrence of this highly clinically significant
endpoint. However, the deficiency of p27 in all lineages, including of the lymphoid lineages,
may have limited extrapolation from this model to other murine models for H. pylori
infection. For example, in contrast to wild-type mice the T cells of p27-deficient mice are
more susceptible to apoptosis following interleukin-2 withdrawal demonstrating the
importance of p27 in the survival of activated T-cells [35]. These mice also have reduced
proliferative capacity of their T-cells, especially the CD8+ subset [36]. While p27 deficiency
does not apparently affect the differentiation of T cells into Th1 versus Th2 subsets, [37]
exaggerated inflammatory responses have been noted in mice populated with p27 deficient
bone marrow [38] suggesting that deficiency of p27 in bone marrow-derived progenitor cells
can promote inflammatory responses. Furthermore, two groups have demonstrated failure of
T-cell tolerance in p27-deficient mice [39,40].
Taken together, these results demonstrate subtle but potentially important abnormalities in
the immune system of p27-deficient mice that should be borne in mind when extrapolating
from the current results to those that might be expected in wild type mice. Future studies are
planned using “humanized” HLA transgenic mice as a bridge to clinical vaccine
development.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Outline of study design.
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Figure 2.

Outline map of H. pylori DNA vaccine construct
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Figure 3.

H. pylori colonization. Quantification of gastric H. pylori colonization was performed by
real-time PCR and expressed as the ratio of H. pylori's SSA gene to mouse GAPDH. Black
bars represent median value of each group. Data analysis by Kruskal-Wallis oneway
analysis of variance followed by Dunn's test demonstrate that the values for mice receiving
DNA IN group were significantly lower than each of the other groups.
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Figure 4.

Cell-mediated response to immunization of p27-deficient mice with HelicoVax A and
HelicoVax B epitopes. Mice were primed with plasmid DNA vaccine and boosted with
peptide pools comprising the HelicoVax A and HelicoVax B epitope sets or vaccine vehicle
containing no epitopes. Splenocyte responses to individual and pooled epitopes were
measured by IFN–γ ELISpot. Data are the mean spot forming cells (SFC) per million
splenocytes for HelicoVax-vaccinated mice (filled bars), SS1 lysate-vaccinated mice (open
bars) and HelicoVax DNA IN (filled circles) and DNA IM (open circles) groups of mice.
Peptide pools 1 to 3 correspond to the epitopes contained in DNA vaccine construct A
(HelicoVaxA), pools 4 to 6 to DNA vaccine construct B (HelicoVaxB).
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HelicoVax T-cell Epitopes. Column 1: peptide ID. Column 2: amino acid sequence. Column 3: GenBank
accession number of parent protein. Column 4: sequence location in protein.

PeptideID

AA SEQUENCE

GenBank
Accession
Number

HP 4001

NDNVRAYGGNIYEGVLINYYKAIDYMLLNDS

GI-15611087

139-173

HP 4007

RSKSKAKVRINDLRWVFSQRLSALVG

GI-15611162

73-99

HP 4009

MLLERSLIRVNKERLQTYLSLYANETSTRLSEV

GI-15611210

141-171

HP 4018

GLHFLGVFRFAFLYKTQSVGLASKS

GI-15611320

571-595

HP 4026

MHQYKRMQTYPVLFAIQKLALENN

GI-15611443

152-176

HP 4029

PAIYFANSSISGYVFLGLKTKRVRLDA

GI-15611469

42-69

HP 4032

AMGFNNYGAILGVRAFNRFAPYKTPIGINLGKN

GI-15611480

9-38

HP 4034

DSMIEIVNANFSLVHRYYHQKAQILGHK

GI-15611489

503-529

HP 4040

YDRWHGAFRLGYTYRINPFVGIYAQ

GI-15611518

165-192

HP 4042

LYFLGGVLRHARGLAAFTNASTNSYKRL

GI-15611528

22-49

Location in Protein
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HP4054

SDVVRTIEAYRMLRPLVIYPF

GI-15611636

340-371

HP 4055

TINVYYFNHGNLSFTYRRQYSLYVGYR

GI-15611681

67-101

HP 4060

LNTWLNMNALAPKILKALYAYGAQGINLGLNL

GI-15611745

177-208

HP 4061

FALVVFVLSVLLMFKQVRIWIYQYH

GI-15611753

174-201

HP 4064

HFSYKRYLINTLRKEFNFLGTPLILNA

GI-15611840

245-272

HP 4065

MKNFSPLYCLKKLKKRHLIALSLPLLSY

GI-15611844

14-42

HP 4067

CHALYNVGRISTYMLLGAITAGLGNS

GI-15611862

53-84

HP 4068

KIMYYILPQVWAWKKWRAKSLEKYCDF

GI-15611868

408-438

HP 4070

QESVKDAYSEFVFALKRLKILKAQMLELQKIN

GI-15611883

112-140

HP 4071

YNTYYKAGGAEVKYFRPYSVYWVYGY

GI-15611916

59-85

HP 4077

REEIEFMKRKYRLMWGKVADMSSVNK

GI-15612040

126-153

HP 4087

MPPIYRAENGLLVIRPLIKVREASS

GI-15612173

29-58

HP 4100

CKTMALALKALGVKRAMVVNGGGTD

GI-15612266

95-125

HP 4111

QKYFNDYLGLSSYGIIKYNYAQANNEKIQQL

GI-15612411

31-61

HP 4117

VWPFESLPSYLQVFVQIVPAYHGISLLG

GI-15612444

59-86

HP 4119

EIKVSSRQKNVALARKLVVYFARLYTPNPTLSLAQF

GI-15612482

49-78

HP 4120

GSSYHASLASVYLFERLAKIRARAILASEYR

GI-15612485

318-345

HP 4126

GEWYLVAMAYNYGLRKVQNAIKAAGTSD

GI-15612545

82-113

HP 4127

WKKLVKRFDVNYQFIPIIKNMLIGASVPQEFL

GI-15612545

47-77

HP 4152

DTAYKMLKANPTLALSAE

GI-15611119

723-740

HP 4153

DMLYKLNESLRIYQNVLSNNQDQL

GI-15612318

39-62

HP 4154

SNRFMLLWKNRYTLAKVQSFKLEPG

GI-15612384

78-102

HP 4156

FEKKLFVMNYPLTLYTTSPYGISEE

GI-15611791

56-80

HP 4157

MEQVIQNYRMIVALIQNKLSDA

GI-15611555

285-306

HP 4160

PFDLKLLEKEFYQNNATSLLVTS

GI-15611379

245-267

HP 4164

NMELKKALRHYLYAQTSNMVINCV

GI-15611135

173-196

HP 4165

GAFYKVWKNANAYIGTTGNPLGID

GI-15611410

344-367
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PeptideID

AA SEQUENCE

GenBank
Accession
Number

HP 4168

INSIPGYVKLFRKAYGSKVKID

GI-15612419

165-186

HP 4169

ESNISRRTAWGSWLQASAPYAIAPV

GI-15611318

115-139

HP 4171

PTNFVLGANIAGFRKVASAMIAQG

GI-15612066

424-447

HP 4174

LEDLLYLINRPAYANAKVSLQADF

GI-15612087

159-182

HP 4175

GAIITGNYALQAKLTGALFSEDK

GI-15612537

201-223

HP 4179

ELVALYQSAKALSAYWLEIE

GI-15611341

413-432

HP 4181

GLIYFFLNANTPSQHGF

GI-15612512

118-134

HP 4189

IKEYQYSGAFKAVFPLKVNQM

GI-15612027

73-93

HP 4192

TPGLLQFYRSALAYQLRDE

GI-15612041

297-315

HP 4193

FGQYKKLVNRFEGVLTGKGLTYGGS

GI-15612066

176-200

HP 4197

ASPYKNMLSLTLNAANGTISVSG

GI-15612049

405-427

HP 4198

LENYRSLNALFTRSLKKERPFDK

GI-15612340

46-68

HP 4199

ALKIEGRTKSSYYAAQTTRIYRLA

GI-15611225

250-273

Location in Protein
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18

17

18

19

Hp
Lysate

pVax

DNA IM

DNA IN

0.5 (0-1.5)

1 (0-1.5)

1 (0-2.5)

1 (0.5-2)

0.5 (0-1.5)*
0.5 (0-3.5)

1 (0.5-2)

Epithelial
Defects

1 (0.5-2) *

Inflammation

0 (0-1)

0.5 (0-1.5)

0 (0-1)

0.5 (0-2.5)

Oxyntic
Atrophy

0 (0-1.5)

0.25 (0-3)

0 (0-1.5)

0.25 (0-2)

Hyperplasia

0.5 (0-1)

0.5 (0-2)

0 (0-2)

0.5 (0-1.5)

Pyloric
Metaplasia

Median (range) of Lesion Index

0 (0-1)

0.5 (0-2.5)

0 (0-1)**

0.5 (0-1.5) **

Dysplasia

Significantly more inflammation, and dysplasia (P< 0.01), comparing H. pylori lysate group with pVax control.

**

Significantly more inflammation (P< 0.05), and dysplasia, comparing H. pylori lysate group with pVax control.

*

N

Group

2 ( 0-7.5 )

3 (0-15)

1(0.5-8.5)

3.5(1-10.5)

Total

Gastric corpus histology was evaluated on a 0-4 scale [21] in mice euthanized 45 weeks after H. pylori-infection. Data are shown as median (range) of
lesion index and analyzed by a Kruskal-Wallis one-way analysis of variance followed by Dunn's test.
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